Literature DB >> 2254113

Primary adjuvant whole abdominal irradiation in ovarian carcinoma.

H Lindner1, H Willich, A Atzinger.   

Abstract

Eighty-four patients with an ovarian carcinoma Stage I-III received an adjuvant whole abdominal irradiation (WAI) with pelvic boost postoperatively. Surgery included a bilateral salpingo-oophorectomy, hysterectomy, and omentectomy in 59% of the patients; in 41% surgery was less radical. For the whole abdominal irradiation we used the moving-strip method on 43 patients. The open-field technique was used on the other patients. Median dose of WAI was 22.5 Gy and median pelvic dose was 45.5 Gy. After a median follow-up of 68.5 months, a 5-year survival rate of 64 +/- 5.7% was determined, as well as a 5-year NED rate of 61.2 +/- 5.7%. Five-year survival rate was 80.1 +/- 7.4% in Stage I, 64.1 +/- 9.7% in Stage II, and 35.4 +/- 11.6% in Stage III. Five-year survival depended on tumor rest significantly. There was a trend to better prognosis when surgery was complete and grade was G1 or G2. The risk factor according to Dembo proved to be the most reliable prognostic factor: the 5-year survival rates were 75.0 +/- 6.3% for patients with intermediate risk and 20.1 +/- 10.4% for those with high risk (p = 0.001). Side effects were generally well tolerated. We only saw one serious complication, a radiation-induced small bowel obstruction.

Entities:  

Mesh:

Year:  1990        PMID: 2254113     DOI: 10.1016/0360-3016(90)90229-d

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation.

Authors:  Umesh Mahantshetty; Swamidas Jamema; Reena Engineer; Deepak Deshpande; Rajiv Sarin; Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Shyamkishore Shrivastava; Luca Cozzi
Journal:  Radiat Oncol       Date:  2010-11-15       Impact factor: 3.481

2.  Whole abdominal radiotherapy in ovarian cancer.

Authors:  Alberto Biete; Izaskun Valduvieco; Angels Rovirosa; Blanca Farrús; Francesc Casas; Carlos Conill
Journal:  Rep Pract Oncol Radiother       Date:  2010-03-23

3.  Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.

Authors:  Nathalie Rochet; Alexandra D Jensen; Florian Sterzing; Marc W Munter; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  BMC Cancer       Date:  2007-12-19       Impact factor: 4.430

4.  Treatment planning of epithelial ovarian cancers using helical tomotherapy.

Authors:  V Jamema Swamidas; Umesh Mahantshetty; Goel Vineeta; Reena Engineer; Deepak D Deshpande; Rajiv Sarin; Shyam Kishore Shrivastava
Journal:  J Appl Clin Med Phys       Date:  2009-10-07       Impact factor: 2.102

5.  Safety and Efficacy of the Metabolic Profiling of the BIMRT Utilizing 18F FDG PET-CT.

Authors:  Ya-Zheng Dang; Dong-Xian Zhang; Guo-Dong Wang; Hong-Liang Zhao; Shi-Gao Huang; Jie Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.